

Study Participation

What will happen during the study?

There are two phases in the study as described below. Total participation will be 10 weeks.

- The first 2 visits of the study are what is called Double- Blind phase. Like flipping a coin, participants have the 50/50 chance to receive the active medication (Pimavanserin) or a placebo pill (like a sugar pill with no effect).
- For the first 2 visits of the study, you will take one pill in clinic prior to assessments.
- The last 6 weeks of the study is what is called Open-Label phase. This means that everyone is on the active medication to be taken daily.
- At the end of the study, you will receive a follow-up call.

How many visits are there?

You will have to complete 5 in-person visits to our study site in White Plains, NY at the Center for Autism and the Developing Brain.

This will involve meetings with the study doctors to check in on the participants health, safety and complete study assessments. Your study partner will also have to attend each in-person visit.

Eligibility Requirements

To be in this study, participants must:

- Be between the ages of 12 and 40
- Have a diagnosis of Autism Spectrum Disorder (ASD) *or exhibit symptoms of ASD or suspected of ASD
- Have a **care/study partner willing to assist with the study

**All participants are administered testing for ASD at the first visit to confirm a diagnosis. Once confirmed, they may continue into the study.*

***The care/study partner is someone who lives with or has frequent contact with the study participant (parent, spouse, friend, etc.) and is willing and able to provide information about the participant and attend some study visits.*

Additional requirements to participate must also be met. The staff at the study site will explain the complete list of requirements.

FAQ's

Does it cost anything to participate?

There is no cost to participate. Qualified participants receive the study medication (either the Study Drug or placebo) and all required study related medical assessments and examinations at no cost.

Compensation is available for those who satisfy applicable study requirements.

Are there any risks to participating in this study?

There may be potential risks to participating in this study. All drugs and medical procedures carry a risk of side effects; therefore, it is possible that participants may experience some.

Please contact the study site and they will explain some of the risks associated with this study.



About the Study

The purpose of this study is to see if a medication called Pimavanserin can help improve behavioral inflexibility and rigid-repetitive behaviors that are associated with Autism.

Currently, Pimavanserin is approved for treatment of hallucinations and delusions associated with Parkinson's disease. The medication is now being studied in those with Autism to study its effect on inflexible behaviors as well as rigid thinking, which means its use in this study is considered investigational.

Interested? Contact us!

Email:

cadbmedicine@cumc.columbia.edu

Phone

914-997-5587

Or Scan the QR Code below to visit our website:



Be a Part of Autism Research on Inflexible and Compulsive Behaviors



CADB Medicine Research Program

